Compare MIRM & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | MGIC |
|---|---|---|
| Founded | 2018 | 1983 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 990.3M |
| IPO Year | 2019 | 1991 |
| Metric | MIRM | MGIC |
|---|---|---|
| Price | $69.90 | $26.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $88.36 | $18.00 |
| AVG Volume (30 Days) | ★ 624.0K | 43.4K |
| Earning Date | 11-04-2025 | 11-18-2025 |
| Dividend Yield | N/A | ★ 2.25% |
| EPS Growth | N/A | ★ 16.15 |
| EPS | N/A | ★ 0.81 |
| Revenue | $471,794,000.00 | ★ $603,216,000.00 |
| Revenue This Year | $53.78 | $12.87 |
| Revenue Next Year | $19.91 | $6.23 |
| P/E Ratio | ★ N/A | $33.01 |
| Revenue Growth | ★ 53.66 | 12.65 |
| 52 Week Low | $36.88 | $11.36 |
| 52 Week High | $78.55 | $27.44 |
| Indicator | MIRM | MGIC |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 66.83 |
| Support Level | $63.23 | $26.61 |
| Resistance Level | $66.77 | $27.44 |
| Average True Range (ATR) | 3.11 | 0.65 |
| MACD | 0.14 | 0.09 |
| Stochastic Oscillator | 62.10 | 77.15 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.